发明授权
US07217797B2 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
有权
通过诱变改变抗体的FcRn结合亲和力或血清半衰期
- 专利标题： Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
- 专利标题（中）： 通过诱变改变抗体的FcRn结合亲和力或血清半衰期
-
申请号： US10687118申请日： 2003-10-15
-
公开(公告)号： US07217797B2公开(公告)日： 2007-05-15
- 发明人: Paul R. Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
- 申请人： Paul R. Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
- 申请人地址： US CA Fremont
- 专利权人： PDL Biopharma, Inc.
- 当前专利权人： PDL Biopharma, Inc.
- 当前专利权人地址： US CA Fremont
- 代理机构： Townsend and Townsend and Crew LLP
- 主分类号： C12P21/08
- IPC分类号： C12P21/08 ; C12P21/06 ; C12P21/04 ; C07K16/00 ; C12N15/00
摘要：
The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
公开/授权文献
信息查询
